Elicio Therapeutics, a clinical-stage biotechnology company (Nasdaq: ELTX) has recently announced the results from the Phase 1 AMPLIFY-201 study on ELI-002. This immunotherapy uniquely targets mKRAS-driven cancers through a three-component lymph node-targeted vaccine. By leveraging the "brain center" of the immune response, Elicio's novel approach to cancer targeting and treatment holds the potential to transform the lives of patients with solid tumors. As clinical trials continue, Elicio Therapeutics is committed to pioneering effective treatments that can revolutionize how cancer is treated and prevented, especially after other procedures have failed.
The innovative biotechnology company was founded in 2011 to explore the viability of ground-breaking Amphiphile technology, developed by Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). Since its establishment, Elicio Therapeutics has remained committed to implementing a multidisciplinary approach to treating aggressive cancers. The company differentiates itself from competitors seeking similar medical solutions by emphasizing the need for therapies that can be manufactured quickly to meet a growing patient population's needs.
